Clinical trials
IPF clinical trials
Below are recruiting ipf clinical trials, each written for real people, not researchers. We’re tracking 43 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07194382RecruitingPhase 2
Testing a new liquid form of nintedanib for IPF
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
Camperdown, New South WalesAges 40 years+ - NCT06747923RecruitingPhase 2
SB17170 for Idiopathic Pulmonary Fibrosis (IPF)
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
GoyangAges 40 years+ - NCT07284602RecruitingPhase 3
Comparing a new drug to pirfenidone for lung scarring
This trial tests a new medicine, LYT-100 (deupirfenidone), against the standard drug pirfenidone for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the new drug works better or has fewer side effects.
Palm Spring, CaliforniaAges 40 years+ - NCT03418350Recruiting
Study how acid reflux may affect lung scarring
This trial studies whether reflux (acid moving up toward the throat) plays a role in idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes scarred. It may help doctors understand triggers that could worsen symptoms and guide more targeted care.
Denver, ColoradoAges 40–95 - NCT06756230Recruiting
Downhill walking exercise for IPF patients
This study tests whether downhill walking improves lung function and exercise ability in people with idiopathic pulmonary fibrosis (IPF). If you can walk on a treadmill and haven't been in a structured exercise program recently, you may qualify.
Istanbul, ÜsküdarAges 18–75 - NCT07082842RecruitingPhase 3
Testing HEC585 tablets for idiopathic pulmonary fibrosis
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
Beijing, Beijing MunicipalityAges 40–80 - NCT07332117Recruiting
Studying body changes in IPF and PPF patients starting anti-fibrotic drugs
This study uses safe, painless scans (like muscle ultrasound and a body composition test) to track changes in muscle and fat in patients with IPF or PPF who are starting anti-fibrotic medication. The goal is to better understand how these treatments affect your body.
LondonAges 18 years+ - NCT07464912RecruitingPhase 3
Testing TDI01 for idiopathic pulmonary fibrosis
This trial tests a new drug called TDI01 to see if it helps people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. You may qualify if you have a confirmed IPF diagnosis and your lung function is stable enough.
Beijing, Beijing MunicipalityAges 40–80 - NCT07652658RecruitingPhase 2
Study of AZD8965 for people with IPF
This trial tests a new drug called AZD8965 for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the drug can help people with IPF either on current treatments or not on standard therapy.
Birmingham, AlabamaAges 40 years+ - NCT06968845RecruitingPhase 2
Study of LTI-03 for Idiopathic Pulmonary Fibrosis
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
Birmingham, AlabamaAges 40 years+ - NCT07743996Recruiting
Emotional and social experiences with fibrosis medications
This study looks at how people with pulmonary fibrosis feel emotionally and socially while taking antifibrotic medications like nintedanib or pirfenidone. It aims to understand the real-world impact of these treatments on daily life.
TokyoAges 40 years+ - NCT05988463RecruitingPhase 1
Study of artesunate for people with idiopathic pulmonary fibrosis
This study tests artesunate, a medicine that may help treat idiopathic pulmonary fibrosis (IPF), a condition that causes lung scarring. It is for people who are already taking other IPF treatments and want to see if adding artesunate can improve their condition.
Stanford, CaliforniaAges 40 years+ - NCT06967805RecruitingPhase 2
Study of MTX-463 for Idiopathic Pulmonary Fibrosis
This trial tests an experimental drug called MTX-463 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if targeting a protein called WISP1 can slow lung scarring and help you breathe better.
Birmingham, AlabamaAges 40 years+ - NCT06951217RecruitingPhase 2
Long-term safety study of an inhaled drug for lung scarring
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
Birmingham, AlabamaAges 18 years+ - NCT05190211Recruiting
Video exercise therapy for idiopathic pulmonary fibrosis
This study tests whether telerehabilitation (supervised exercise/therapy by video or remote tools) can help people with idiopathic pulmonary fibrosis (IPF) improve breathing and function. You may be able to take part if your condition has been stable and you haven’t recently done a pulmonary rehab program.
Istanbul, ZeytinburnuAges 18–75 - NCT05147597Recruiting
Study tests a Turkish questionnaire for lung scarring
This study checks whether a Turkish version of a symptom questionnaire works reliably for people with idiopathic pulmonary fibrosis. It may help clinics better understand symptoms and track changes over time.
Istanbul, ÜsküdarAges 18 years+ - NCT07192939RecruitingPhase 2
Testing HRS-9813 for progressive pulmonary fibrosis
This trial tests a new drug called HRS-9813 for people with pulmonary fibrosis (scarring in the lungs) that continues to worsen. It looks at whether the drug can slow down the disease compared to a placebo.
Beijing, Beijing MunicipalityAges 21 years+ - NCT07448194RecruitingPhase 1
Safety study of HW241045 in healthy adults
This trial tests the safety of a new drug called HW241045 in healthy volunteers. It helps doctors understand how the drug affects the body and if it causes any side effects.
BeijingAges 18–55 - NCT07036523RecruitingPhase 2
Study of BI 765423 for people with Idiopathic Pulmonary Fibrosis (IPF)
This trial tests a new medicine, BI 765423, to see if it can improve lung function in people with IPF, a lung scarring disease. You can join whether or not you are already taking standard treatments like nintedanib or pirfenidone.
Birmingham, AlabamaAges 40 years+ - NCT07723872Recruiting
Finger vs. earlobe oxygen test during a 6-minute walk
This study compares oxygen levels measured at the finger versus the earlobe during a 6-minute walk test for people with interstitial lung disease. It helps find the most accurate way to monitor your oxygen during exercise.
Granollers, SpainAges 18 years+ - NCT07679893RecruitingPhase 2
Inhaled nintedanib for idiopathic pulmonary fibrosis
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
Windsor, OntarioAges 40–80 - NCT07707245Recruiting
Finding biomarkers in lung disease and lung cancer
This trial studies blood and tissue samples from people with COPD, IPF, or lung cancer to find markers that can help diagnose and predict these conditions. It aims to discover why some lung diseases progress to cancer.
Milan, MilanAges 18 years+ - NCT03478553Recruiting
Study of genes in people with pulmonary fibrosis
This study looks at genetic (inherited) factors related to pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF). It may help researchers understand why some families are more affected and could guide future testing or treatments.
Aurora, ColoradoAges 18 years+ - NCT04442711Recruiting
Study of worsening lung symptoms in people with IPF
This study looks at people with idiopathic pulmonary fibrosis (IPF) who are currently having a sudden worsening of breathing symptoms. It may help doctors better understand what happens during these flare-ups and how to manage them.
Hellerup, CopenhagenAges 18 years+
Hear when a new IPF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ipf?
- Yes. Clin2 currently lists 43 recruiting ipf studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ipf trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ipf trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.